Tcr2 Therapeutics Stock Revenue
Tcr2 Therapeutics fundamentals help investors to digest information that contributes to Tcr2 Therapeutics' financial success or failures. It also enables traders to predict the movement of Tcr2 Stock. The fundamental analysis module provides a way to measure Tcr2 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tcr2 Therapeutics stock.
Tcr2 |
Tcr2 Therapeutics Company Revenue Analysis
Tcr2 Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Tcr2 Therapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Tcr2 Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tcr2 Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tcr2 Therapeutics could also be used in its relative valuation, which is a method of valuing Tcr2 Therapeutics by comparing valuation metrics of similar companies.Tcr2 Therapeutics is currently under evaluation in revenue category among its peers.
Tcr2 Fundamentals
Return On Equity | -0.91 | |||
Return On Asset | -0.35 | |||
Current Valuation | (73.69 M) | |||
Shares Outstanding | 39.26 M | |||
Shares Owned By Insiders | 1.50 % | |||
Shares Owned By Institutions | 54.31 % | |||
Number Of Shares Shorted | 360.89 K | |||
Price To Book | 0.22 X | |||
EBITDA | (89.62 M) | |||
Net Income | (151.82 M) | |||
Cash And Equivalents | 175.99 M | |||
Cash Per Share | 4.55 X | |||
Total Debt | 58.23 M | |||
Debt To Equity | 0.29 % | |||
Current Ratio | 5.02 X | |||
Book Value Per Share | 2.58 X | |||
Cash Flow From Operations | (101.46 M) | |||
Short Ratio | 1.29 X | |||
Earnings Per Share | (4.20) X | |||
Target Price | 6.43 | |||
Number Of Employees | 58 | |||
Beta | 1.93 | |||
Market Capitalization | 58.11 M | |||
Total Asset | 208.24 M | |||
Retained Earnings | (501.34 M) | |||
Working Capital | 113.56 M | |||
Z Score | -3.54 | |||
Net Asset | 208.24 M |
Pair Trading with Tcr2 Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tcr2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to PepsiCo could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PepsiCo when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PepsiCo - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PepsiCo to buy it.
The correlation of PepsiCo is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PepsiCo moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PepsiCo moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PepsiCo can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |